Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is one of the best yield companies with high dividend expectations.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The group usually releases earnings worse than estimated.
  • With an enterprise value anticipated at 4.21 times the sales for the current fiscal year, the company turns out to be overvalued.
  • With a 2017 P/E ratio at 27.96 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 59.9 USD
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK AND COMPANY-6.96%153 659
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
AMGEN19.97%128 363
SANOFI-4.32%109 438
BRISTOL-MYERS SQUIBB COMPAN..6.81%103 145
NOVO NORDISK A/S29.49%102 404
BAYER5.62%102 387
ABBOTT LABORATORIES42.38%95 629
ELI LILLY AND COMPANY17.54%95 432
GLAXOSMITHKLINE-17.57%85 531
CELGENE CORPORATION-8.35%85 030
ASTRAZENECA9.90%82 666
ALLERGAN PLC-20.10%57 457
More Results
Financials ($)
Sales 2017 40 235 M
EBIT 2017 13 720 M
Net income 2017 5 245 M
Debt 2017 13 787 M
Yield 2017 3,31%
P/E ratio 2017 27,96
P/E ratio 2018 18,35
EV / Sales 2017 4,21x
EV / Sales 2018 4,09x
Capitalization 156 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing -
Middle Term Timing -
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart MERCK AND COMPANY
Duration : Period : Day
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Duration : Period : Week
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders